Antitumor cyclopalladated complexes with low toxicity to laboratory animals have shown leishmanicidal effect. These findings stimulated us to test the leishmanicidal property of one palladacycle compound called DPPE 1.2 on Leishmania (Leishmania) amazonensis, an agent of simple and diffuse forms of cutaneous leishmaniasis in the Amazon region, Brazil.
Promastigotes of L. (L.) amazonensis and infected bone marrow-derived macrophages were treated with different concentrations of DPPE 1.2. In in vivo assays foot lesions of L. (L.) amazonensis-infected BALB/c mice were injected subcutaneously with DPPE 1.2 and control animals received either Glucantime or PBS. The effect of DPPE 1.2 on cathepsin B activity of L. (L.) amazonensis amastigotes was assayed spectrofluorometrically by use of fluorogenic substrates. The main findings were: 1) axenic L. (L.) amazonensis promastigotes were destroyed by nanomolar concentrations of DPPE 1.2 (IC50 = 2.13 nM); 2) intracellular parasites were killed by DPPE 1.2 (IC50 = 128.35 nM), and the drug displayed 10-fold less toxicity to macrophages (CC50 = 1,267 nM); 3) one month after intralesional injection of DPPE 1.2 infected BALB/c mice showed a significant decrease of foot lesion size and a reduction of 97% of parasite burdens when compared to controls that received PBS; 4) DPPE 1.2 inhibited the cysteine protease activity of L. (L.) amazonensis amastigotes and more significantly the cathepsin B activity.
The present results demonstrated that DPPE 1.2 can destroy L. (L.) amazonensis in vitro and in vivo at concentrations that are non toxic to the host. We believe these findings support the potential use of DPPE 1.2 as an alternative choice for the chemotherapy of leishmaniasis.
Leishmaniasis is an important public health problem with an estimated annual incidence of 1.5 million of new human cases of cutaneous leishmaniasis and 500,000 of visceral leishmaniasis. Treatment of the diseases is limited by toxicity and parasite resistance to the drugs currently in use, validating the need to develop new leishmanicidal compounds. We evaluated the killing by the palladacycle complex DPPE 1.2 of Leishmania (Leishmania) amazonensis, an agent of human cutaneous leishmaniasis in the Amazon region, Brazil. DPPE 1.2 destroyed promastigotes of L. (L.) amazonensis in vitro at nanomolar concentrations, whereas intracellular amastigotes were killed at drug concentrations 10-fold less toxic than those displayed to macrophages. L. (L.) amazonensis-infected BALB/c mice treated by intralesional injection of DPPE 1.2 exhibited a significant decrease of foot lesion sizes and a 97% reduction of parasite burdens when compared to untreated controls. Additional experiments indicated the inhibition of the cathepsin B activity of L. (L.) amazonensis amastigotes by DPPE 1.2. Further studies are needed to explore the potential of DPPE 1.2 as an additional option for the chemotherapy of leishmaniasis.
Citation: Paladi CdS, Pimentel IAS, Katz S, Cunha RLOR, Judice WAdS, Caires ACF, et al. (2012) In Vitro and In Vivo Activity of a Palladacycle Complex on Leishmania (Leishmania) amazonensis. PLoS Negl Trop Dis 6(5): e1626. doi:10.1371/journal.pntd.0001626
Editor: Timothy G. Geary, McGill University, Canada
Received: October 6, 2011; Accepted: March 8, 2012; Published: May 15, 2012
Copyright: © 2012 Paladi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Protozoan parasites of the Leishmania genus induce cutaneous, mucocutaneous and visceral diseases in man and animals. According to the World Health Organization, about 1.5 million of new human cases of cutaneous leishmaniasis and 500,000 of visceral leishmaniasis are registered annually . Leishmania (Leishmania) amazonensis, one of the causative agents of human cutaneous leishmaniasis in the Amazon region, Brazil, is associated with both the simple and diffuse forms of the disease . The first-line drugs used for treatment of leishmaniasis are pentavalent antimonial compounds, while amphotericin B and pentamidine are used as the second-line chemotherapy. However, the use of these compounds is limited by toxicity to the host and the development of resistance by the parasites , . Thus, the development of new leishmanicidal drugs is an important goal and several compounds including synthetic, natural products extracted from plants and marine sources have shown different degrees of efficacy in the treatment of experimental leishmaniasis –. The in vitro and in vivo demonstration that the viability of the Leishmania parasites is reduced by inhibitors of cysteine proteases – encouraged the use of virtual screening to identify additional inhibitors , . The demonstration that antitumor drugs may also display antileishmanial activity has also stimulated the screening of these compounds in vitro and in clinical trials . Cyclopalladated complexes have shown in vitro and in vivo antitumor activity and low toxicity in animals – and more recently one of them exhibited lethal effects on human leukaemia cells while was ineffective against normal human lymphocytes . The leishmanicidal and tripanocidal activity of cyclopalladated complexes has also been demonstrated –. Furthermore, there is evidence that palladacycle complexes may destroy tumoral cells by inhibition of cathepsin B activity and their inhibitory effect on Leishmania cysteine proteases in vitro was also demonstrated , . The present study describes the effect of one palladacycle compound called DPPE 1.2 on promastigotes, intracellular amastigotes and cutaneous lesions in mice infected with L. (L.) amazonensis.
Eight-week-old female Golden hamsters were obtained from breeding stocks maintained at the Universidade de Campinas (São Paulo, Brazil) and female BALB/c mice 6 to 8 weeks old were acquired from Universidade Federal de São Paulo (São Paulo, Brazil). This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the Brazilian National Council of Animal Experimentation (http://www.cobea.org.br). The protocol was approved by the Committee on the Ethics of Animal Experiments of the Institutional Animal Care and Use Committee at the Federal University of São Paulo (Id # CEP 1844/08).
The L. (L.) amazonensis strain used (MHOM/BR/1973/M2269) was kindly provided by Dr. Jeffrey J. Shaw, Instituto Evandro Chagas, Belém, Pará, Brazil and maintained as amastigotes by inoculation into footpads of Golden hamsters every 4 to 6 weeks. Amastigote suspensions were prepared by homogenization of excised lesions, disruption by four passages through 22-gauge needles, and centrifugation at 250×g for 10 min; the resulting supernatant was centrifuged at 1,400×g for 10 min, and the pellet was resuspended in RPMI 1640. The suspension was kept under agitation for 4 h at room temperature and centrifuged at 250×g for 10 min. The final pellet contained purified amastigotes which were essentially free of contamination by other cells .
L. (L.) amazonensis promastigotes were grown at 26°C in 199 medium (Gibco) supplemented with 4.2 mM sodium bicarbonate, 4.2 mM HEPES, 1 mM adenine, 5 µg/ml hemin (bovine type I) (Sigma, St Louis, MO, USA) and 10% fetal calf serum (FCS) (Cultilab, SP, Brazil).
Biphosphinic palladacycle complex [Pd(C2, N-S(-)DMPA)(DPPE)]Cl (DPPE 1.2)
The palladacycle compound DPPE 1.2 (Figure 1) was obtained from N,N-dimethyl-1-phenethylamine (DMPA), complexed to 1,2-ethane-bis (diphenylphosphine) (DPPE) ligand and synthesized as previously described . Stock solutions at 1.45 mM were prepared in dimethylsulfoxide (DMSO); for in vitro use, the drug was diluted to the appropriate concentration in cell culture medium, and for in vivo injections the stock was diluted in PBS.
Effect of DPPE 1.2 on L. (L.) amazonensis promastigotes and intracellular amastigotes
The promastigote cultures at 1×106 parasites/ml were kept in 199 culture medium as described above containing between 1.25 nM and 150 nM of DPPE 1.2. Parasites were counted daily in a Neubauer chamber for three days. The leishmanicidal effect of DPPE 1.2 on intracellular amastigotes was evaluated in mouse bone marrow derived macrophages infected with L. (L.) amazonensis. Bone marrow-derived macrophages were generated from bone marrow stem cells isolated from BALB/c mice . Cells were counted, added (8×105) and cultured on glass coverslips inserted in 24-well tissue culture plates containing RPMI 1640 medium buffered with 15 mM of HEPES, 20 mM of sodium bicarbonate and supplemented with 1 mM L-glutamine, 20% of fetal calf serum (FCS) and 30% L929 cell conditioned medium (LCCM). Cultures were kept at 37°C in an atmosphere of air/CO2 (95/5%). After 5 days, the medium was changed for RPMI containing 10% of FCS and macrophages were infected at a multiplicity of 2 amastigotes per macrophage. After 24 h, infected cultures were treated with different drug concentrations (150 to 500 nM) for 3 days. The coverslips were fixed with methanol, stained with hematoxylin-eosin (HE) and intracellular amastigotes were counted. Results are expressed by the infection index, obtained by multiplying the percentage of infected macrophages by the average number of amastigotes per macrophage. At least 200 macrophages were scored in each 3 coverslips. Amphotericin B (Sigma-Aldrich, St Louis, MO, USA) and Glucantime (Sanofi-Aventis, Brazil, 300 mg/ml, 81 mg/ml SbV) were used as standard drugs for treatment of L. (L.) amazonensis promastigotes and intracellular amastigotes, respectively.
DPPE 1.2 cytotoxicity to macrophages was tested by a MTT micromethod described previously  after incubation of bone marrow derived macrophages with 150 to 2,000 nM of DPPE 1.2 for 3 days. Macrophages were also incubated with the highest concentration of DMSO used for DPPE 1.2 solubilization (0.04%). The formation of formazan was measured by adding 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT; Molecular Probes, Eugene, OR, USA) 0.5 mg/ml and incubation of the cultures at 37°C in the dark. After 4 h the medium was removed, 200 µl of DMSO was added per well and the absorbance was measured using an ELISA reader at 540 nm (Labsystems Multiskan).
Antileishmanial in vivo assays
For evaluation of in vivo leishmanicidal activity of DPPE 1.2 female BALB/c mice 6 to 8 weeks-old were infected subcutaneously at the right hind-foot with 1×105 L. (L.) amazonensis amastigotes. Fifteen days after infection, the animals were randomly separated in 3 groups of 12 mice each. Treated animals received in the foot lesions every other day doses of 60 mg/kg/day (16.8 mg [Sbv]/kg/day) of Glucantime for 1 month (total of 900 mg/kg–252 mg [Sbv]/kg/day) or doses of 320 µg/kg/day of DPPE 1.2 (total of 4.8 mg/kg). Stock solutions of DPPE 1.2 were prepared daily in PBS after solubilization in DMSO (final concentration of 0.1%). Control group received the same number of injections of PBS. Infection was monitored once a week by measuring the diameter of foot lesions with a dial caliper (Mitutoyo Corp., Japan). Parasite burden from infected feet was determined by a limiting dilution method, as previously described .
Toxicity for mice assays
Serum concentrations of urea, creatinine, bilirubin and transaminases were determined in BALB/c mice at the end of treatment, using sets of commercial reagents (Doles Reagentes e Equipamentos para Laboratórios, Ltda, Brazil).
Proteolytic activity of L. (L.) amazonensis promastigotes and amastigotes was determined by zymography employing electrophoretic separation of parasite lysates under unheated and nonreduced conditions resolved on 10% acrylamide gels containing 0.1% copolymerized gelatin (Gibco-BRL) by low-voltage (50 V) electrophoresis . Proteolytic activity in the gels was detected after 1 h of incubation, under agitation, in 0.1 M sodium acetate buffer, pH 5.0, containing 2.5% Triton X-100, followed by 2 h of incubation in the acetate buffer in the absence of Triton X-100 and Coomassie blue staining. Some gel strips after electrophoresis were incubated in buffer solutions in the presence of either protease inhibitor E-64 (trans-epox-isuccinil-L-leucinamide-(4-guanide-butane)or orthophenanthroline or DPPE 1.2. Molecular weight markers (Pharmacia LKB) were visible on the background of stained gelatin when used in a 5-fold excess.
Inhibition of L. (L.) amazonensis cathepsins by DPPE 1.2
Cathepsin activities were monitored with the fluorogenic substrates Z-Phe-Arg-AMC (for all cathepsins), Z-Arg-Arg-AMC (for cathepsin B), and Z-Leu-Arg-AMC (for cathepsins K, V, and S) (commercially obtained from Sigma, St. Louis, MO, USA) using 1 µl of L. (L.) amazonensis amastigote cell lysate (1×109 amastigotes disrupted in 200 µl PBS), 2 mM DTT (dithiothreitol), 1 ml of four-component buffer comprised of 25 mM acetic acid, 25 mM Mes (4-Morpholineethanesulfonic acid), 75 mM Tris, and 25 mM glycine, pH 5.0, 10 µM of each fluorogenic substrate and 50 µM of DPPE 1.2. The effect of DPPE 1.2 on the parasite enzyme activity was tested by incubation of the L. (L.) amazonensis lysate with DPPE 1.2 for 2 minutes in the buffer solution a 37°C; the fluorogenic substrate was then added and the fluorescence of the released fluorophore, 7-amino-4-methylcoumarine (AMC), was measured over time. The remaining enzyme activities were determined and expressed as a percentage of the activity of the control experiment. Parasite lysate was also incubated with 10 µM of the fluorogenic substrate Abz-Gly-Ile-Val-Arg-Ala-Lys(Dnp)-OH (Sigma, St. Louis, MO, USA), specific for cathepsin B , in the presence of either increasing concentrations of DPPE 1.2 or CA074, a specific inhibitor of cathepsin B. The cathepsin activity was monitored spectrofluorometrically using the fluorogenic substrates on a Hitachi F-2000 spectrofluorometer equipped with a thermostated cell holder. The fluorescence excitation (λEx) and emission (λEm) wavelengths, for the fluorescence of AMC, were set at 380 nm and 460 nm, respectively, while the parameters for the fluorescence of Abz-peptide fragments resulting from the Abz-Gly-Ile-Val-Arg-Ala-Lys(Dnp)-OH hydrolysis were set at λEx = 320 and λEm = 420 nm.
To determine the statistical differences between groups ANOVA and Student's t test were used and P values<0.05 or lower were considered statistically significant. IC50 and CC50 values were determined by GraphPad Prism, version 5.0.
Inhibitory activity of DPPE 1.2 on growth of L. (L.) amazonensis promastigotes
Axenic cultures of L. (L.) amazonensis promastigotes were grown in the presence of 1.25 to 150 nM of DPPE 1.2. Significant inhibition of parasite growth was detected after 2 and 3 days of treatment with 1.25 to 25 nM of DPPE 1.2. At 75 and 150 nM the drug inhibited 84% and 96%, respectively, of parasite growth 1 day after treatment and nearly 100% of promastigotes were killed after 2 and 3 days in the presence of these concentrations of DPPE 1.2. A growth curve similar to control was observed when L. (L.) amazonensis promastigotes were cultured in the presence of the highest concentration of DMSO used for DPPE 1.2 solubilization (0.04%). As a control drug parasites were grown in the presence of amphotericin B. After 72 of incubation, the IC50 values for both drugs were determined (Table 1).
Leishmanicidal activity of DPPE 1.2 on L. (L.) amazonensis-infected macrophages
Treatment with DPPE 1.2 resulted in a significant, dose-dependent decrease in infection index of L. (L.) amazonensis-infected macrophages with an inhibition of 92% for 500 nM of DPPE 1.2 (IC50 of 128.35 nM; 95% confidence limits, 111.2–164.2 nM) (Figure 2A). Infected cultures were also treated with the highest concentration of DMSO used for DPPE 1.2 solubilization (0.04%); these concentrations did not reduce the viability or the infection of macrophages (data not shown). The cytotoxicity of DPPE 1.2 on macrophages was evaluated by the MTT method and the CC50 was determined (1,267 nM; 95% confidence limits, 1,15–1,52 nM).
Macrophages were infected with amastigotes of L. (L.) amazonensis for 24 h at 37°C, the drugs were added and infection index was calculated after 72 h of treatment. *P<0.001 and #P<0.05 compared to control.
Figure 2B). The IC50 value expressed as µg/ml of pentavalent antimony [Sbv] was 178.5 µg/ml (95% confidence limits, 108.1–294.6 µg/ml) and treatment with the drug at this concentration resulted in 40% of macrophage toxicity (data not shown). The calculated CC50 for Glucantime expressed as µg/ml of pentavalent antimony [Sbv] was 266.3 µg/ml (95% confidence limits, 252.2–290.3 µg/ml).
Effect of DPPE 1.2 on BALB/c mice infected with L. (L.) amazonensis
BALB/c mice infected with L. (L.) amazonensis were treated every other day with 320 µg/kg/day of DPPE 1.2 for 1 month injected in foot lesions. As can be observed in Figure 3, starting from 24 days of treatment the animals which received DPPE 1.2 showed a significant decrease of foot lesion size compared to controls. Starting from 16 days of treatment, the animals that received Glucantime also exhibited significantly smaller foot lesions compared to untreated control, as well as to animals treated with DPPE 1.2.
A -Development of foot lesions in L. (L.) amazonensis-infected BALB/c mice treated with DPPE 1.2. The treatment was started 15 days after infection and continued for 5 weeks. Data points represent the average measurements for 3 groups of twelve mice each; B - Macroscopical evaluation of lesions in untreated (left column), DPPE 1.2-treated mice (medium column), and Glucantime-treated mice (right column) 60 days post-infection. *P<0.01 and **P<0.001 compared to untreated animals; #P<0.001 compared to animals treated with DPPE 1.2. Data are representative of three independent experiments.
Parasite load was also evaluated by limiting dilution in foot lesions of BALB/c mice one month after end of the treatment with either DPPE 1.2 or Glucantime. Figure 4 shows that BALB/c mice treated with either DPPE 1.2 or Glucantime displayed a reduction of parasite load of 97% and 99%, respectively, compared to untreated animals.
Number of parasites recovered by limiting dilution from L. (L.) amazonensis-infected mice treated with DPPE 1.2. Parasites were quantified one month after interruption of treatment. *P<0.001.
To evaluate hepato and nephrotoxicity of DPPE 1.2 serum levels of transaminases, urea and creatinine were determined. No statistically significant alterations were detected between groups (data not shown).
Effect of DPPE 1.2 on proteolytic activity of L. (L.) amazonensis
Parasite proteolytic activity was determined by zymography after electrophoresis of L. (L.) amazonensis extracts in SDS-PAGE with gelatin coupled gels. Figure 5A shows that most of the proteolytic activity of L. (L.) amazonensis promastigotes that migrates as a 60 kDa band was abolished in the presence of orthophenanthroline, while DPPE 1.2 did not show any effect on this activity. On the other hand, amastigotes displayed a strong activity at a molecular mass of 30–35 kDa that was totally inhibited by either DPPE 1.2 or E-64, indicating that DPPE 1.2 inhibits cysteine protease activity of L. (L.) amazonensis amastigotes.
A - Extracts of promastigotes (P) and amastigotes (AM) of L. (L.) amazonensis were separated by SDS-PAGE on a 10% acrylamide gel containing 0.1% gelatin under nonreducing conditions. Numbers at left indicate apparent molecular masses in kilodaltons. B - Fluorogenic substrates with different specificities for cathepsin-like proteases were incubated with extracts of L. (L.) amazonensis amastigotes in absence or presence of DPPE 1.2, as indicated. C – Fluorogenic substrate specific for cathepsin B-like proteases was incubated with extracts of L. (L.) amazonensis in presence of increasing concentrations of DPPE 1.2.
A spectrofluorometric assay using specific substrates for cathepsins in the presence of DPPE 1.2 was also carried out. Figure 5B shows that the L. (L.) amazonensis amastigote extract exhibited high hydrolytic activity on all substrates tested. Although DPPE 1.2 inhibited the enzymatic activity on all substrates, a significantly higher reduction on cathepsin B activity could be observed in the presence of this palladacycle complex (75%). Figure 5C shows that the activity of L. (L.) amazonensis extract on a most specific substrate for cathepsin B was significantly inhibited either by DPPE 1.2 or CA074 (data not shown). The calculated IC50 values for DPPE 1.2 and CA074 were not significantly different (2.25±0.11 µM and 0.7±0.08 µM, respectively), strongly suggesting that DPPE 1.2 inhibits L. (L.) amazonensis cathepsin B.
The present results document the leishmanicidal effect of the palladacycle complex DPPE 1.2 on L. (L.) amazonensis. This compound destroyed L. (L.) amazonensis promastigotes at very low concentrations. Extension of this study to L. (L.) amazonensis-infected macrophages also showed an effective leishmanicidal activity of DPPE 1.2 against amastigotes, whereas the drug displayed 10-fold less toxicity to macrophages. Although similar leishmanicidal effect was observed with Glucantime, significantly higher concentrations of this antimonial were necessary to destroy L. (L.) amazonensis amastigotes. The leishmanicidal activity of DPPE 1.2 is comparable to that obtained with several compounds tested against L. (L.) amazonensis like mesoionic salt derivatives, primary S-nitrosothiols, aureobasidin A, julocrotine, tamoxifen, elatol –. However, higher concentrations of these compounds were used to destroy L. (L.) amazonensis, whereas an effective leishmanicidal effect was observed with DPPE 1.2 at nanomolar range. The leishmanicidal activity of metal complexes of gold, platinum, iridium, rhodium and osmium has also been investigated. However, most of them destroyed only L. (L.) donovani promastigotes, while few reduced the parasitism in infected animals –, impairing the comparison with DPPE 1.2 data. Among other palladium complexes previously tested against Leishmania only one was an effective inhibitor of promastigote growth, while none of them reduced the intracellular amastigote burden .
The leishmanicidal effect of DPPE 1.2 was also demonstrated in vivo. Although the reduction of parasite load in foot lesions of L. (L.) amazonensis-infected mice treated with DPPE 1.2 was similar to that obtained with Glucantime, this antimonial compound was used in 200 times higher concentration. Treatment with DPPE 1.2 led to a significant reduction of parasite load in foot lesions (97%), but did not result in sterile cure in infected mice. However, it is important to emphasize that the BALB/c strain is highly susceptible to L. (L.) amazonensis infection. These mice develop a gradual increase of foot lesions characterized by a large infiltrate of macrophages harboring a high number of amastigotes, thus mimicking the anergic form of diffuse cutaneous leishmaniasis caused by L. (L.) amazonensis . The apparent lack of toxicity of DPPE 1.2 to BALB/c mice was demonstrated by hepatic and renal function assays after treatment with the drug, corroborating data that showed the low toxicity of palladacycle complexes in the treatment of mice against tumor cells . More recently, the high selectivity index of one cyclopalladacycle complex with trypanocidal activity was also demonstrated, suggesting the use of this compound for treatment of Chagas' disease .
As reported in the literature, the antitumor property of palladacycle complexes can be attributed, at least in part, to their inhibitory activity on the cysteine protease cathepsin B . This information led us to test for the possible effect of DPPE 1.2 on L. (L.) amazonensis protease activity. We showed that DPPE 1.2 did not inhibit the activity of the metalloprotease gp63, the major surface protein of Leishmania promastigotes . On the other hand, the high cysteine protease activity expressed in L. (L.) amazonensis amastigotes was inhibited by DPPE 1.2 and the most significant inhibition was observed on the cathepsin B activity. However, the drug did not affect the cysteine proteinase activity of mouse macrophages (data not shown). Several studies demonstrated the involvement of cathepsin L-like (cpL) and cathepsin B-like (cpB) in Leishmania growth and virulence in vitro and in vivo –. Furthermore, cysteine proteinase inhibitors have been reported to kill Leishmania in vitro and in vivo –. In the present study we show that in vitro DPPE 1.2 inhibited L. (L.) amazonensis cathepsin B at higher concentrations than those necessary to kill L. (L.) amazonensis. These findings argue against a relationship between the leishmanicidal effect of DPPE 1.2 and the inhibition of L. (L.) amazonensis cathepsin B and suggest that other relevant targets may account for the leishmanicidal effect of the drug. Palladacycle complexes have been associated with organelle-specific effects in tumor cells such as the lysosomal and mitochondrial permeabilization that can trigger apoptosis , . The induction of L. (L.) amazonensis apoptosis by DPPE 1.2 has not been investigated.
Leishmania killing is associated to macrophage activation by IFN-γ and TNF-α and the production of nitric oxide , whereas TGF-β is an immunosupressor cytokine known to exacerbate visceral and cutaneous leishmaniasis –. Interestingly, Leishmania cathepsin B is involved in the conversion of latent TGF-β to its biologically active form . Since we have shown here that DPPE 1.2 inhibits parasite cathepsin B, killing of L. (L.) amazonensis in infected mice treated with the drug may be associated to protective responses arising from lower expression of the active form of TGF-β. This possibility is now under investigation.
In conclusion, the effectiveness of DPPE 1.2 in destroying L. (L.) amazonensis in vitro and by intralesional administration in vivo at concentrations non toxic to the host support further studies of the leishmanicidal activity of the palladacycle as an additional choice to available chemotherapies.
We are grateful to Michel Rabinovitch for critically reading the manuscript, for pertinent suggestions and helpful discussions. We also thank Adriana K. Carmona for kindly provided the cathepsin B inhibitor CA074, and Diego Magno Assis and Luiz Juliano for providing the substrate Abz-Gly-Ile-Val-Arg-Ala-Lys(Dnp)-OH.
Conceived and designed the experiments: CdSP WAdSJ ACFC CLB. Performed the experiments: CdSP IASP SK RLORC WAdSJ. Analyzed the data: CdSP CLB. Contributed reagents/materials/analysis tools: CdSP IASP SK RLORC. Wrote the paper: CdSP CLB.
- 1. WHO (2010) Control of leishmaniasis. Report of the Expert Committee. World Health Organization. Tech Rep Ser 949: 1–186.
- 2. Lainson R, Shaw JJ (1987) Evolution, classification and geographical distribution. In: Peters W, Killick-Kendrick E, editors. The Leishmaniases in Biology and Medicine. London: Academic Press. pp. 1–120.
- 3. Goto H, Lindoso JA (2010) Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 8: 419–433.
- 4. Polonio T, Efferth T (2008) Leishmaniasis: drug resistance and natural products (review). Int J Mol Med 22: 277–286.
- 5. Tiuman TS, Santos AO, Ueda-Nakamura T, Filho BP, Nakamura CV (2011) Recent advances in leishmaniasis treatment. Int J Infect Dis 15: 525–532.
- 6. Sen R, Chatterjee M (2011) Plant derived therapeutics for the treatment of Leishmaniasis. Phytomedicine 18: 1056–1069.
- 7. Tempone AG, Martins de Oliveira C, Berlinck RG (2011) Current approaches to discover marine antileishmanial natural products. Planta Med 77: 572–585.
- 8. Maekawa Y, Himeno K, Ishikawa H, Hisaeda H, Sakai T, et al. (1998) Switch of CD4+ T cell differentiation from Th2 to Th1 by treatment with cathepsin B inhibitor in experimental leishmaniasis. J Immunol 161: 2120–2127.
- 9. Ponte-Sucre A, Vicik R, Schultheis M, Schirmeister T, Moll H (2006) Aziridine-2,3-dicarboxylates, peptidomimetic cysteine protease inhibitors with antileishmanial activity. Antimicrob Agents Chemother 50: 2439–2447.
- 10. Selzer PM, Pingel S, Hsieh I, Ugele B, Chan VJ, et al. (1999) Cysteine protease inhibitors as chemotherapy: lessons from a parasite target. Proc Natl Acad Sci U S A 96: 11015–11022.
- 11. Desai PV, Patny A, Sabnis Y, Tekwani B, Gut J, et al. (2004) Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database. J Med Chem 47: 6609–6615.
- 12. Desai PV, Patny A, Gut J, Rosenthal PJ, Tekwani B, et al. (2006) Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory. J Med Chem 49: 1576–1584.
- 13. Fuertes MA, Nguewa PA, Castilla J, Alonso C, Pérez JM (2008) Anticancer compounds as leishmanicidal drugs: challenges in chemotherapy and future perspectives. Curr Med Chem 15: 433–439.
- 14. Caires ACF (2007) Recent advances involving palladium (II) complexes for the cancer therapy. Anticancer Agents Med Chem 7: 484–491.
- 15. Higgins JD, Neely L, Fricker S (1993) Synthesis and cytotoxicity of some cyclometallated palladium complexes. J Inorg Biochem 49: 149–156.
- 16. Rodrigues EG, Silva LS, Fausto DM, Hayashi MS, Dreher S, et al. (2003) Cyclopalladated compounds as chemotherapeutic agents: antitumor activity against a murine melanoma cell line. Int J Cancer 107: 498–504.
- 17. Oliveira CR, Barbosa CMV, Nascimento FD, Lanetzki CS, Meneghin MB, et al. (2009) Pre-clinical antitumor evaluation of biphosphinic palladacycle complex in human leukaemia cells. Chem-Biol Interact 177: 181–189.
- 18. Fricker SP, Mosi RM, Cameron BR, Baird I, Zhu Y, et al. (2008) Metal compounds for the treatment of parasitic diseases. J Inorg Biochem 102: 1839–1845.
- 19. Matsuo AL, Silva LS, Torrecilhas AC, Pascoalino BS, Ramos TC, et al. (2010) In vitro and in vivo trypanocidal effects of the cyclopalladated compound 7a, a drug candidate for treatment of Chagas' disease. Antimicrob Agents Chemother 54: 3318–3325.
- 20. Navarro M, Betancourt A, Hernández C, Marchán E (2008) Palladium polypyridyl complexes: synthesis, characterization, DNA interaction and biological activity on Leishmania (L.) mexicana. J Braz Chem Soc 19: 1355–1360.
- 21. Bincoletto C, Tersariol IL, Oliveira CR, Dreher S, Fausto DM, et al. (2005) Chiral cyclopalladated complexes derived from N,N-dimethyl-1-phenethylamine with bridging bis(diphenylphosphine)ferrocene ligand as inhibitors of the cathepsin B activity and as antitumor agents. Bioorg Med Chem 13: 3047–3055.
- 22. Barbiéri CL, Doine AI, Freymuller E (1990) Lysosomal depletion in macrophages from spleen and foot lesions of Leishmania-infected hamster. Exp Parasitol 71: 218–228.
- 23. Zamboni DS, Rabinovitch M (2003) Nitric oxide partially controls Coxiella burnetii phase II infection in mouse primary macrophages. Infect Immun 71: 1225–1233.
- 24. Dutta A, Bandyopadhyay S, Mandal C, Chatterjee M (2005) Development of a modified MTT assay for screening antimonial resistant field isolates of Indian visceral leishmaniasis. Parasitol Int 54: 119–122.
- 25. Lima HC, Bleyenberg JA, Titus RG (1997) A simple method for quantifying Leishmania in tissues of infected animals. Parasitol Today 13: 80–82.
- 26. Robertson CD, Coombs GH (1990) Characterisation of three groups of cysteine proteases in the amastigotes of Leishmania mexicana mexicana. Mol Biochem Parasitol 42: 269–276.
- 27. Cotrin SS, Puzer L, Judice WAS, Juliano L, Carmona AK, et al. (2004) Positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides to define substrate specificity of carboxypeptidases: assays with human cathepsin B. Anal Biochem 335: 244–252.
- 28. da Silva EF, Canto-Cavalheiro MM, Braz VR, Cysne-Finkelstein L, Leon LL, et al. (2002) Synthesis, and biological evaluation of new 1,3,4-thiadiazolium-2-phenylamine derivatives against Leishmania amazonensis promastigotes and amastigotes. Eur J Med Chem 37: 979–984.
- 29. de Souza GF, Yokoyama-Yasunaka JK, Seabra AB, Miguel DC, de Oliveira MG, et al. (2006) Leishmanicidal activity of primary S-nitrosothiols against Leishmania major and Leishmania amazonensis: implications for the treatment of cutaneous leishmaniasis. Nitric Oxide 15: 209–216.
- 30. dos Santos AO, Veiga-Santos P, Ueda-Nakamura T, Filho BP, Sudatti DB, et al. (2010) Effect of elatol, isolated from red seaweed Laurencia dendroidea, on Leishmania amazonensis. Mar Drugs 8: 2733–2743.
- 31. Guimarães LR, Rodrigues AP, Marinho PS, Muller AH, Guilhon GM, et al. (2010) Activity of the julocrotine, a glutarimide alkaloid from Croton pullei var. glabrior, on Leishmania (L.) amazonensis. Parasitol Res 107: 1075–1081.
- 32. Miguel DC, Yokoyama-Yasunaka JK, Andreoli WK, Mortara RA, Uliana SR (2007) Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes. J Antimicrob Chemother 60: 526–534.
- 33. Tanaka AK, Valero VB, Takahashi HK, Straus AH (2007) Inhibition of Leishmania (Leishmania) amazonensis growth and infectivity by aureobasidin A. J Antimicrob Chemother 59: 487–492.
- 34. Croft SL, Craciunescu DG, Certad-Fombona G (1992) The activity of platinum, iridium, and rhodium drug complexes against Leishmania donovani. Trop Med Parasitol 43: 24–28.
- 35. Mesa-Valle CM, Rodriguez-Cabezas MN, Moraleda-Lindez V, Craciunescu D, Sanchez-Moreno M, et al. (1998) In vitro and in vivo activity of two Pt(IV) salts against Leishmania donovani. Pharmacology 57: 160–172.
- 36. Mesa-Valle CM, Moraleda V, Lazuen J, Craciunescu D, Osuna A (1997) Action of new organometallic complexes against Leishmania donovani. J Antimicrob Chemother 40: 47–57.
- 37. Etges R, Bouvier J, Bordier C (1986) The major surface protein of Leishmania promastigotes is a protease. J Biol Chem 261: 9098–9101.
- 38. Mottram JC, Brooks DR, Coombs GH (1998) Roles of cysteine proteases of trypanosomes and Leishmania in host-parasite interactions. Cur Opin Microbiol 1: 455–460.
- 39. Bart G, Frame MJ, Carter R, Coombs GH, Mottram JC (1997) Cathepsin B-like cysteine protease-deficient mutants of Leishmania mexicana. Mol Biochem Parasitol 88: 53–61.
- 40. Mottram JC, Souza AE, Hutchison JE, Carter R, Frame MJ, et al. (1996) Evidence from disruption of the lmcpb gene array of Leishmania mexicana that cysteine proteases are virulence factors. Proc Natl Acad Sci U S A 93: 6008–6013.
- 41. Barbosa CM, Oliveira CR, Nascimento FD, Smith MC, Fausto DM, et al. (2006) Biphosphinic palladacycle complex mediates lysosomal-membrane permeabilization and cell death in K562 leukaemia cells. Eur J Pharmacol 542: 37–47.
- 42. Santana DP, Faria PA, Paredes-Gamero EJ, Caires ACF, Nantes IL, et al. (2009) Palladacycles catalyse the oxidation of critical thiols of the mitochondrial membrane proteins and lead to mitochondrial permeabilization and cytochrome c release associated with apoptosis. Biochem J 417: 247–256.
- 43. Bogdan C, Röllinghoff M (1998) The immune response to Leishmania: mechanisms of parasite control and evasion. Int J Parasitol 28: 121–134.
- 44. Barral-Netto M, Barral A, Brownell CE, Skeiky YA, Ellingsworth LR, et al. (1992) Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 257: 545–548.
- 45. Pinheiro RO, Pinto EF, Lopes JR, Guedes HL, Fentanes RF, et al. (2005) TGF-beta-associated enhanced susceptibility to leishmaniasis following intramuscular vaccination of mice with Leishmania amazonensis antigens. Microbes Infect 7: 1317–1323.
- 46. Rodrigues V, Silva JS, Campos-Neto A (1998) Transforming growth factor β and immunosuppression in experimental visceral leishmaniasis. Infect Immun 66: 1233–1236.
- 47. Wilson ME, Young BM, Davidson BL, Mente KA, McGowan SE (1998) The importance of TGF-beta in murine visceral leishmaniasis. J Immunol 161: 6148–6155.
- 48. Somanna A, Mundodi V, Gedamu L (2002) Functional analysis of cathepsin B-like cysteine proteases from Leishamnia donovani complex. Evidence for the activation of latent transforming growth factor beta. J Biol Chem 277: 25305–25312.